Novel T cell interferon gamma release assay (IGRA) using spike recombinant protein for COVID19 vaccine response and Nucleocapsid for SARS-Cov2 response

Glucocorticoid use as a cause of non-cellular immune response to SARS-Cov2 Spike in patients with immune system diseases

“…The vaccinated healthy control (HC) group comprised 81 staff members from the medical laboratory of the University Hospital of Toulouse (CHU de Toulouse, Occitania, France) and blood bank donors (EFS Toulouse, Occitania, France), part of them were previously described [ 7 ]. Among the 81 vaccinated HC, 13 had developed a COVID-19 infection.…”

“…As previously described [ 7 ], the blood samples were drawn into heparinized tubes (Becton Dickinson, Heidelberg, Germany), and 1 mL of whole blood was distributed in 4 tubes with: (i) 20 μL of SARS-Cov2 full-length Spike protein (2 μg/tube); (ii) 2 μL of SARS-Cov2 Nuc protein (2 μg/tube); (iii) 20 μL of RMPI (negative control); and (iv) 20 μL of phytohemagglutinin (PHA, 40 μg/mL). Endotoxin free Spike and Nuc recombinant proteins were produced by INVIVOGEN® (Toulouse, France) based on the initial strain protein sequences [ 8 ].…”

“…However, such a strategy does not take into account the protection due to memory T lymphocytes. To explore the latter, we have recently developed a whole blood interferon gamma release assay (IGRA) using SARS-Cov2 purified proteins from Spike and Nucleocapsid (Nuc) to evaluate the T cell immune response to COVID-19 vaccine and natural infection, respectively [ 7 ]. In the present study, we describe the humoral and T-cell response of various ISD patients following COVID-19 vaccination or infection.…”

Immunity after COVID-19 Recovery and Vaccination: Similarities and Differences

“…IGRA is a whole-blood assay based on the ELISA assessment of the level of interferon-gamma released upon stimulation with target antigens—either recombinant viral proteins [ 23 ] or synthetic peptide pools [ 24 , 25 ]. Numerous IGRAs are commercially available, including QuantiFERON SARS-CoV-2 assay (Qiagen, Düsseldorf, Germany) and Quan-T-cell SARS-CoV-2 (Euroimmun, Lubeck, Germany).…”

The mosaic of autoimmunity – Finally discussing in person. The 13th international congress on autoimmunity 2022 (AUTO13) Athens

“…Interestingly, interferon gamma release assay (IGRA) was suggested to be beneficial for testing the cellular response after SARS-CoV-2 vaccination, especially in immunocompromised patients such as those with steroid therapy. The findings were presented by Renaudineau and colleagues during the session based on their newly published data [ 64 ].…”